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Abstract
Background: Over the last two decades, there have been several improvements in the management of diabetes.
Whether this has impacted on the epidemiology and outcome of diabetic ketoacidosis (DKA) requiring intensive
care unit (ICU) admission is unknown.
Method: This was a retrospective study of 8533 patients with the diagnosis of DKA admitted to 171 ICUs in Australia
and New Zealand between 2000–2013 with separate independent analysis of those on established insulin (Group I) or
not on insulin (Group NI) at the time of hospitalisation.
Results: Of the 8553 patients, 2344 (27 %) were identified as NI. The incidence of ICU admission with DKA
progressively increased fivefold from 0.97/100,000 (95 % CI 0.84–1.10) in 2000 to 5.3/100,000 (95 % CI 4.98–5.53) in 2013
(P < 0.0001), with the proportions between I and NI remaining stable. Rising incidences were observed mainly in rural
and metropolitan hospitals (P < 0.01). In the first 24 hours in the ICU, mean worst pH increased over the study period
from 7.20 ± 0.02 to 7.24 ± 0.01 (P < 0.0001), and mean lowest plasma bicarbonate from 12.1 ± 6.6 to 13.8 ± 6.6 mmol/L
(P < 0.0001). In contrast, mean highest plasma glucose decreased from 26.3 ± 14 to 23.2 ± 13.1 mmol/L (P < 0.0001).
Hospital mortality was significantly greater in NI as compared to I (2.4 % vs 1.1 %, P > 0.0001). Elevated plasma urea in
the first 24 hours (≥25 mmol/L, adjusted odds ratio 20.6 (6.54–65.7), P < 0.0001) was the strongest individual predictor
of mortality.
Conclusions: The incidence of ICU admission of patients with DKA in Australia and New Zealand has increased fivefold
over the last decade, with a significant proportion of patients not on insulin at presentation. Overall physiological status
in the first 24 hours of ICU admission has progressively improved and mortality rates have remained stable. However,
DKA patients not on established insulin therapy at presentation had significantly worse outcomes. This notion has
epidemiologic, diagnostic and management implications.
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Background
Type 1 diabetes mellitus affects children and adults world-
wide, with an increasing incidence amongst young people
[1]. Patients with type 1 diabetes are at risk of developing
diabetic ketoacidosis (DKA). The epidemiology of
DKA is variable [2–4], and mortality rates range from
2 to 40 % depending on the region [5–12]. In addition,
it is now recognized that some patients with type 2
diabetes may also present with DKA. This syndrome,
known as ketosis-prone diabetes, was originally described
in the African–Americans and Hispanics [13, 14]. It has
now been reported in all other races [15–18]. DKA in pa-
tients with type 1 diabetes is well characterized. However,
the epidemiology, physiological status and outcome of
DKA in type 2 diabetes have not been reported in detail;
for example, it is likely that these are older patients with
co-existing illnesses who as a consequence may have
worse outcomes, but the absence of data from large
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intensive care registries makes this an unknown at any
national level.
In the last two decades, diabetes management has
undergone paradigm shifts with increased public health
education, improved insulin delivery methods, better tar-
geting of oral hypoglycaemic agents and more intensive
monitoring [19, 20]. It is likely that these initiatives have
resulted in changes in the incidence, early metabolic
control or even survival of DKA.
Accordingly, we evaluated trends in epidemiology, meta-
bolic control and mortality in a large cohort of patients ad-
mitted to Australian and New Zealand intensive care units
(ICUs) with DKA from 2000 to 2013. We hypothesized
that metabolic derangements and mortality rates have im-
proved significantly over this period, that patients with
DKA not on established insulin therapy at presentation
have a worse outcome, and that metabolic abnormalities in
the first 24 hours of ICU admission can be identified that
help predict mortality.
Methods
We conducted a retrospective study using data from the
Australian and New Zealand Intensive Care Society Adult
Patient Database (ANZICS APD) run by the Centre for
Outcome and Resource Evaluation. The ANZICS APD is a
high-quality bi-national database that captures more than
90 % of all ICU admissions in Australia and New Zealand
[21]. The study was approved by the Alfred Hospital
Human Research Ethics Committee, Melbourne, Australia,
with a waiver of informed consent.
Description of patients
We included all patients aged over 16 years admitted
with a primary diagnosis of DKA to an adult ICU in
Australia and New Zealand during a 14-year period from
1 January 2000 to 31 December 2013. ICU readmissions
and episodes with no documented mortality outcome
were excluded.
We analysed all hospital outcomes (mortality, discharge
home, discharge to other hospital, and discharge to re-
habilitation). ‘Discharge to rehabilitation’ included discharge
to rehabilitation facilities and chronic care facilities such as
nursing homes.
The ANZICS APD records the highest and lowest
glucose measurements in the first 24 hours of the ICU
admission. Patients were classified as those who were
on chronic insulin therapy (Group I) prior to admission
or not on chronic insulin therapy (Group NI) at presen-
tation. No data on therapy or specific treatments prior
to or within the ICU are available in the APD, other than
the provision of mechanical ventilation. Standard base ex-
cess (SBE) values were calculated from arterial blood gas
values (pH and PaCO2) recorded for the Acute Physiology
and Chronic Health Evaluation (APACHE) II scoring
system [22].
Patients were analysed according to the following sub-
groups: I vs NI diabetes, the degree of SBE derangement,
and presence or absence of comorbidities as defined by
the APACHE II scores and hospital type. Acute renal
failure was defined as present when the 24 hour urine
output was <410 ml, or creatinine ≥133 μmol/L and the
patient is not receiving chronic dialysis. Hospitals were
classified as tertiary, metropolitan, rural/regional or pri-
vate based on the location of the hospital and the level
of care provided. All patients with an admission diagno-
sis of DKA were analysed to determine annual incidence
trends. As previous diabetic status became part of the
mandatory minimum dataset in 2007 and was not col-
lected by all hospitals until that time, only those with
known prior diabetic status and complete glucose mea-
surements were included in the analysis of factors asso-
ciated with mortality.
Statistical analysis
Data are presented as percentages and numbers, means
with standard deviations, medians and interquartile ranges
(IQRs), or proportions and 95 % confidence intervals
(CIs). Chi square tests for equal proportion, t tests, or
Wilcoxon rank sum tests were used to test for differences
as appropriate.
Logistic regression models were used to investigate the
change in hospital outcomes over time for all patients
with known pre-admission diabetic status, fitting main
effects for DKA, year of admission and illness severity,
with patients nested within site and site treated as a ran-
dom effect. To facilitate a measure of patient severity in-
dependent of pH, glucose and sodium, and to assess the
independent association of these factors to mortality,
each patient’s predicted risk of death was calculated in
accordance with the Australia and New Zealand risk of
death (ANZROD) methodology [23] after separate removal
of the pH, glucose, urea, creatinine, potassium and sodium
components. ANZROD is an updated mortality prediction
model specifically calibrated for use in Australian and New
Zealand ICUs. It has been derived from components of
the APACHE II and III scoring systems with additional
diagnostic variables, and combines eight risk adjustment
algorithms, one for each major diagnostic group. It has
been shown to have significantly better calibration and
discrimination than APACHE III. All data were analysed
by SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA). A
two-sided P value of 0.01 was considered to be statistically
significant.
Results
Between January 2000 and December 2013 there were
1,259,892 adult ICU admissions in Australia and New
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Zealand listed in the ANZICS APD. After exclusion of re-
admissions and episodes without documented mortality
outcomes, 1,163,051 patient datasets were available for
analysis. Of these 12,577 (1.1 %) were listed as admissions
for DKA, forming the cohort examined to determine
trends in admission to ICU over the study period. Of
these, 8553 with documentation of both plasma glucose
concentrations and previous diabetic status formed the
cohort analysed to determine factors associated with
outcome (Fig. 1). Comorbidities were present in 923
patients (11 %).
The population incidence of ICU admission with DKA
progressively increased from 0.97/100,000 (95 % CI
0.84–1.10) in 2000 to 5.3/100,000 (95 % CI 4.98–5.53) in
2013 (P < 0.0001). An increasing proportion of DKA ad-
missions relative to total ICU admissions was observed in
rural (P = 0.0003) and metropolitan hospitals (P = 0.01),
whilst tertiary centres showed a declining trend (P = 0.006)
(Fig. 2).
Of the 8553 patients, 2344 (27 %) belonged to the NI
group. Overall mean age was 39 ± 18 years with the vast
majority originating directly from the Emergency Depart-
ment. The median duration of time spent in the hospital
prior to ICU admission was 4 hours (IQR 1.8–6.5). Over-
all, 1 % of patients were recorded as having suffered a
cardiac arrest and 7 % as requiring mechanical ventila-
tion. There was a reduction in mean APACHE II score
from 13.7 ± 6.1 to 12.1 ± 6.8 (P < 0.0001), and time spent
Fig. 1 CONSORT flow diagram. ANZICS Australian and New Zealand Intensive Care Society, DKA Diabetic ketoacidosis
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in the hospital prior to ICU admission decreased from a
median of 4.3 hours (IQR 1.54–7.62) to 3.68 hours (IQR
1.83–5.82) (P = 0.006).
Changes in physiological parameters over time
There was a clear annual trend towards improved acid–
base status and glucose control over the study period. The
mean worst pH in the first 24 hours progressively in-
creased from 7.20 ± 0.02 (IQR 7.09–7.3) in 2000 to 7.24 ±
0.01 (IQR 7.15–7.34) in 2013 (P < 0.0001) (Fig. 3), the
mean lowest plasma bicarbonate increased from 12.1 ± 6.6
to 13.8 ± 6.6 mmol/L (P < 0.0001), and the mean SBE in-
creased from –16 ± 8 to –13 ± 8 mmol/L (P < 0.0001). The
mean highest plasma glucose in the first 24 hours de-
creased over the study period from 26.3 ± 14.8 to 23.2
± 13.1 mmol/L (P < 0.0001).
Outcomes
Median ICU length of stay increased progressively over
the study period from 32.7 (IQR 19.8–56.4) to 41.7 (IQR
Fig. 2 Incidence of ICU DKA admissions across different categories of ICUs. Error bars represent 95 % confidence intervals
Fig. 3 Annual trends in acid–base status. Standard base excess (SBE) is expressed in mmol/L. Error bars represent standard errors
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24.8–67.3) hours (P = 0.0004), whereas median hospital
length of stay declined from 109 (IQR 72.8–212) to
87 (IQR 50.3–166) hours (P < 0.0001). The unadjusted
ICU and hospital mortality rates for the entire study
period were 0.7 % and 1.4 %, respectively. The in-
crease in mortality between ICU and hospital dis-
charge was confined almost exclusively to the NI
group of patients. Although we observed a reduction
in raw mortality (Fig. 4), there was no change in risk-
adjusted mortality during the 14-year study period
after accounting for declining severity of illness. Ana-
lysis of survival trends over three different epochs
(2000–2004, 2005–2009, 2010–2013) did not identify
any differences in mortality. About 98 % of the I
cohort and patients and 96 % of the NI cohort were
discharged home, the remainder to a rehabilitation or
chronic care facility.
Comparison of Group I and Group NI DKA
Patients in Group I were younger with a lower
prevalence of chronic co-morbidities such as liver
disease, immune-suppression and malignancies. This
group had better glucose control and better renal
function in the first 24 hours, while those in the
NI group had less severe disorders of acid–base sta-
tus. Mortality and ICU and hospital lengths of stay
were significantly higher in the NI cohort patients
(Table 1).
Comparison of survivors and non-survivors
Non-survivors were older and more likely to have experi-
enced cardiac arrest and mechanical ventilation (Table 2).
They had lower Glasgow Coma Score values, higher
plasma glucose concentrations, higher arterial PCO2 and
lower pH values, and higher plasma urea and creatinine
concentrations. However, there was no difference in the
degree of overall metabolic acidosis as evidenced by SBE
values (Tables 3, 4, 5, 6 and 7). Those who died also had a
longer duration of stay in ICU and hospital. Using multi-
variable logistic regression analysis, the strongest indi-
vidual independent predictor of mortality was a high
plasma urea concentration. For those with elevated plasma
urea >25 mmol/L, the adjusted odds ratio for death was
20.6 (95 % CI 6.4–65.7) (P < 0.0001) (Table 7).
Sensitivity analyses
Trends in metabolic status (pH, SBE, glucose), illness se-
verity, length of stay and mortality were analysed after
stratifying for hospital category and size. In addition, we
analysed all outcomes in the subgroup of ICUs that con-
tinuously contributed to the ANZICS APD. Findings
were similar to those noted in the overall cohort of pa-
tients, with no evidence of differences in outcome across
different hospital categories or sizes.
Given the large size of the study cohort, we also exam-
ined the database for missing data and, in such instances,
additional sensitivity analyses were performed whereby all
patients with missing data were included in the analysis as
Fig. 4 Observed in-hospital mortality (with 95 % confidence interval) of admissions to ICU due to DKA between 2000 and 2013. P value for trend
for raw mortality = 0.028, unadjusted for declining severity of illness
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a separate variable. The proportions missing were very
small for serum sodium (2.6 %), potassium (2.7 %), urea
(1 %) and creatinine (3 %). The results from the additional
sensitivity analyses were concordant with those from the
original results. The proportion missing for pH was
23.4 %. Nevertheless, there was no significant relation-
ship between pH and mortality in this cohort regardless
of whether missing patients were included or not.
Table 1 Comparison of diabetic ketoacidosis in patients on established chronic insulin therapy (I) vs. not on chronic insulin therapy
(NI)
I diabetes (n = 6209) NI diabetes (n = 2344) P value
Age (years) 36.68 (17.35) 44.89 (19.61) <0.0001
APACHE II score 39 (27–54) 45 (31–61) <0.0001
Weight (kg) 69.34 (18.26) 76.75 (23.66) <0.0001
Chronic respiratory disease 1 % (90) 2 % (41) 0.31
Chronic cardiovascular disease 3 % (188) 4 % (87) 0.11
Chronic liver disease 0 % (30) 2 % (36) <0.0001
Chronic renal failure 3 % (169) 3 % (60) 0.68
Immune disease 0 % (29) 1 % (27) 0.0005
Immunosuppressed by therapy 1 % (54) 2 % (49) <0.0001
Metastases 0.3 % (20) 1.4 % (32) <0.0001
Leukaemia 0.1 % (7) 0.5 % (11) 0.001
Cardiac arrest in the previous 24 hours 1 % (37) 1 % (14) 0.99
Physiological derangement
Mean arterial pressure (mmHg) 87.56 (22.93) 89.74 (24.37) 0.0001
Mechanical ventilation in first 24 hours 6 % (385) 9 % (204) <0.0001
Glasgow Coma Score 14.16 (2.17) 13.96 (2.43) 0.0002
Acute renal failure 5 % (292) 7 % (162) <0.0001
24 hour urine output (mL) 2468 (1500–3700} 2505 (1590–3800) 0.003
Laboratory derangements
Arterial pH 7.24 (7.12–7.32) 7.27 (7.16–7.36) <0.0001
Arterial PCO2 (mmHg) 29 (23–35) 31 (24–38) <0.0001
Bicarbonate (mmol/L) 13.82 (6.73) 15.56 (7.57) <0.0001
Standard base excess (mEq/L) −14.51 (8.43) −12.07 (9.27) <0.0001
PaO2 (mmHg) 104.2 (59.88) 106.38 (63.9) 0.2
Sodium (mmol/L) 137.88 (7.25) 139.22 (9.68) <0.0001
Potassium (mmol/L) 4.4 (3.6–5) 4.2 (3.4–4.8) <0.0001
Urea (mmol/L) 6.8 (4.3–11.6) 7.6 (4.5–14.8) <0.0001
Creatinine (μmol/l) 91 (55–136) 100 (65–152) <0.0001
Albumin (mmol/L) 31.16 (6.8) 30.43 (6.73) <0.0001
Bilirubin (mmol/L) 8 (5–14) 8 (5–13) 0.96
Highest glucose (mmol/L) 23.5 (13.07) 24.29 (14.35) 0.015
Lowest glucose (mmol/L) 7.1 (5.2–10) 8 (5.6–11.7) <0.0001
Outcomes
ICU mortalitya 0.6 % (34) 1.1 % (26) 0.006
Hospital mortality 1.1 % (67) 2.4 % (56) <0.0001
ICU length of stay (hours) 41.6 (24–64.2) 46.5 (26.8–73.7) <0.0001
Hospital length of stay (days) 3.75 (2.39–6.74) 5.12 (3.03–9.65) <0.0001
Values represent worst recorded in first 24 hours of ICU admission unless stated
aDeaths during the initial admission to ICU
APACHE Acute Physiology and Chronic Health Evaluation, ICU Intensive care unit
Figures in brackets indicate actual numbers or range or SD as appropriate
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Table 2 Comparison of survivors and non-survivors with diabetic ketoacidosis
Label Alive Died P value
n = 8430 n = 123
“I” diabetes 73 % (6142) 54 % (67) <0.0001
Age (years) 38.56 (18.13) 64.14 (16.93) <0.0001
APACHE II score 44.31 (23.17) 94.5 (34.95) <0.0001
Weight (kg) 71.23 (20.04) 71.33 (20) 0.99
Chronic respiratory disease 1 % (118) 11 % (13) <0.0001
Chronic cardiovascular disease 3 % (257) 15 % (18) <0.0001
Chronic liver disease 1 % (62) 3 % (4) 0.002
Chronic renal failure 3 % (217) 10 % (12) <0.0001
Immune disease 1 % (53) 2 % (3) 0.013
Immunosuppressed by therapy 1 % (97) 5 % (6) 0.0002
Metastases 1 % (44) 7 % (8) <0.0001
Leukaemia 0.2 % (15) 2.4 % (3) <0.0001
Cardiac arrest in the previous 24 hours 1 % (41) 9 % (10) <0.0001
ICU admission source: operating theatre 1 % (48) 1 % (1) 0.72
ICU admission source: emergency 87 % (7361) 82 % (101) 0.09
ICU admission source: ward 4 % (307) 11 % (14) <0.0001
Physiological derangement
Mean arterial pressure (mm Hg) 88.32 (23.22) 77.13 (28.88) <0.0001
Mechanical ventilation in first 24 hours 6 % (537) 42 % (52) <0.0001
Glasgow Coma Score 14.16 (2.14) 10.13 (4.56) <0.0001
Acute renal failure 5 % (419) 28 % (35) <0.0001
24 hour urine output (mL) 2540 (1600–3800) 1335 (515–1953) <0.0001
Laboratory derangements
Arterial pH 7.22 (0.16) 7.18 (0.2) 0.004
Arterial PCO2 (mmHg) 29.67 (11.16) 34.36 (11.19) <0.0001
Bicarbonate (mmol/l) 14.28 (7.01) 16.07 (7.4) 0.006
Standard base excess (mEq/L) −13.83 (8.74) –13.2 (8.69) 0.46
PaO2 (mmHg) 114.46 (67) 134.47 (96.1) 0.003
Sodium (mmol/L) 138 (135–142) 142 (136–147) <0.0001
Potassium (mmol/L) 4.37 (1.07) 4.75 (1.23) 0.0001
Urea (mmol/L) 6.9 (4.3–12.1) 17.3 (11.9–25.55) <0.0001
Creatinine (μmol/L) 93 (57–140) 191 (120–267) <0.0001
Albumin (mmol/L) 31.0 (6.76) 26.1 (7.08) <0.0001
Bilirubin (mmol/L) 8 (5–14) 11 (6–19) 0.02
Highest glucose (mmol/L) 23.6 (13.31) 32.3 (18.73) <0.0001
Lowest glucose (mmol/L) 7.4 (5.3–10.3) 9.6 (6.1–15.3) <0.0001
Haematocrit 0.38 (0.08) 0.34 (0.09) <0.0001
White cell count 14.6 (10.2–20.6) 16.8 (11.5–22.5) 0.04
Length of stay outcomes
ICU length of stay (hours) 42.8 (24.7–66.8) 66.1 (31.3–156.2) <0.0001
Hospital length of stay (days) 4.01 (2.58–7.41) 5.75 (2.04–14.86) 0.022
Values represent worst recorded in first 24 hours of ICU admission unless stated
APACHE Acute Physiology and Chronic Health Evaluation, I Insulin, ICU Intensive care unit
Figures in brackets indicate actual numbers or range or SD as appropriate
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A comparison of the two population cohorts (those in-
cluded in and those excluded from the analysis) revealed
no statistically significant differences in demographics
and APACHE II scores, proportion of patients on estab-
lished insulin therapy, highest glucose, lowest plasma bi-
carbonate, and urea (P = not significant) and clinically
insignificant differences in pH (7.25 vs 7.23) and PCO2
(30 vs 29) (P < 0.0001), suggesting that the cohort in-




We studied the epidemiology, early physiological features,
and outcomes of patients admitted to Australia and New
Zealand ICUs with the diagnosis of DKA over more than a
decade. We found a fivefold increase in the incidence of
ICU admission and demonstrated that more than a quarter
of patients were not on insulin at presentation. As a pro-
portion of overall ICU admissions, DKA increased progres-
sively in rural and metropolitan ICUs but decreased in
tertiary centres, while physiological status in the first 24
hours of ICU admission improved significantly. Moreover,
although overall ICU and hospital mortality remained low,
patients not on insulin at presentation (the NI cohort) had
a worse outcome compared to those with a history of prior
insulin therapy (the I cohort). Finally, an elevated plasma
urea concentration was strongly independently associated
with mortality.
Comparison with previously studies
We identified a change in epidemiology with an in-
creased population incidence of ICU admission of DKA.
This may reflect multiple factors. These include the rising
population incidence of diabetes in Australia and New
Zealand [24, 25], the widespread availability via govern-
ment subsidy of glucometers which also measure ketones
and facilitate earlier hospital presentation, the introduc-
tion of requirements for mandatory rapid patient process-
ing in Australian Emergency Rooms [26], and more liberal
and frequent ICU admission for further resuscitation and
stabilization. Finally, the increased use of short-acting
prandial insulin analogues and basal-bolus regimes may
have also contributed by reducing the “overlap” in insulin
actions, thus increasing the possibility of insulinopaenia,
especially if a dose is missed (a common occurrence) [27].
More than a quarter of our ICU patients with DKA
had no history of prior insulin therapy. The absence of
pre-existing insulin therapy suggests two possible diagno-
ses: a) type 2 diabetes-associated DKA or b) a first presen-
tation of type 1 diabetes-associated DKA. However, the
older age in the NI cohort combined with the greater
prevalence of comorbidities and the higher mortality des-
pite less severe acid–base derangements is strongly sug-
gestive of the former. This is also consistent with the
changing epidemiology of type 2 diabetes, the incidence of
which is rising [24], with patients diagnosed at a younger
age and living longer due to improved cardiovascular out-
comes. The longer disease duration means many more
patients are treated with insulin [24, 27] and have reduced
endogenous insulin secretory capacity. The resultant en-
dogenous insulinopaenia may make them more “like” type
1 diabetes, and hence prone to DKA.
An increasing proportion of patients with DKA were
admitted to rural and regional ICUs. This phenomenon
may in part reflect improved ICU staffing with certified
intensive care specialists in peripheral units [28]. This
may also reflect a lack of high dependency unit facilities
in smaller centres, fewer available general and endocrine
physicians and less favourable nurse–patient ratios on
the medical floor. In addition, over the study period the
proportion of rural ICUs increased by 312 %, metropol-
itan ICUs by 230 % and tertiary ICUs by 135 %. These
structural factors could account for the trend towards
greater increase in the incidence in rural and metropol-
itan centres and may also account for the progressive
increase in ICU length of stay noted in our study,
Table 3 Multivariable logistic regression model for factors
associated with in-hospital mortality: highest glucose in first 24
hours
Adjusted odds ratio (95 % CI) P value
ANZROD 1.12 (1.10–1.15) <0.001
Highest glucose in
first 24 hours (mmol)
0.002





ANZROD Australian and New Zealand risk of death model with glucose
components removed, CI Confidence interval
Table 4 Multivariable logistic regression model for factors
associated with in-hospital mortality: lowest pH in first 24 hours
Adjusted odds ratio (95 % CI) P value
ANZROD 1.13 (1.11–1.15) <0.001
Lowest pH in first
24 hours (mmol)
0.31





ANZROD Australian and New Zealand risk of death model with pH components
removed, CI Confidence interval
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similar to reports in epidemiological studies of DKA in
the USA [29].
We found a low mortality rate. DKA mortality rates in
other studies have ranged from 2–40 %, although com-
parison is limited by their small sample sizes (all <250
patients) [7–12, 30–33] and the fact that not all patients
were admitted to ICU. Most were single centre studies
dating back to the early 1990s and may not reflect more
recent developments in diabetes. Our mortality data
also compare favourably with those from two other
large national non-ICU registries from Denmark [6]
and the USA (n = 15,994) [29]. A large Italian registry
comprising >250,000 acute hyperglycaemic complications
reported annual trends and a step-wise reduction in hos-
pitalisation for diabetic complications, but did not provide
specific data for DKA [3]. An Australian tertiary centre
study [34] of trends in deaths associated with hypergly-
caemic emergencies between 1973 and 1988 reported a
mortality rate of 4.9 % in patients with DKA but also did
not focus on ICU patients.
Our study provides evidence that DKA-related ICU
and hospital mortality has remained steady for nearly a
decade and a half in conjunction with improved metabolic
control. The secular trend in improved acid–base status
and glucose values on ICU day 1 could be attributed to
several factors including earlier presentation, improved re-
suscitation in Emergency Departments and subsequently
in ICU, plus a background of better diabetic management
in the community. The question remains as to why,
despite an improved physiological status over time, no
improvement in mortality was observed. The hospital
mortality in DKA is very low to start with, about 1.5 %.
To demonstrate an improvement in mortality with such
low baseline mortality rates is very difficult. Moreover,
this is a retrospective study and therefore difficult to
adjust for a number of confounding variables. Although
there is a rising incidence of type 2 diabetes in the com-
munity and therefore a tendency for worse outcomes
[24, 25], our database did not capture information on
the type of diabetes and therefore it is difficult to attri-
bute the lack of a decline in mortality to an increasing
proportion of type 2 diabetes. Moreover, neither the mean
age nor the body weight or chronic cardiovascular disease
showed an increasing trend over the study period to sug-
gest a greater proportion of type 2 diabetes.
Elevated urea concentrations stood out above glucose,
sodium and potassium concentrations as a strong inde-
pendent predictor of mortality. Although plasma urea is
dependent on both renal function and pre-renal factors
such as hydration and catabolic status, its strong rela-
tionship with mortality in this dataset appeared inde-
pendent of renal function. This is in conjunction with
the finding of sodium >155 mmol/L associated with an
odds ratio for death >2 (Table 5), suggesting that dehy-
dration may be an important marker of illness severity.
The other possible explanation is that elevated urea is
also a sign of protein catabolic state which may be seen in
severe DKA. Also urea elevation out of proportion to cre-
atinine could indicate gastrointestinal bleeding secondary
to stress ulceration suggesting a severe form of DKA.
Implications of study findings
Our ICU data demonstrate significant changes in the
epidemiology, management and some outcomes of DKA
in Australia and New Zealand, with several factors po-
tentially driving such changes. As discussed, the sizeable
proportion of ICU DKA patients not on insulin at pres-
entation were at greater risk of unfavourable outcomes
despite less severe acid–base disturbances, suggesting
that the majority had type 2 diabetes. On the other hand,
some patients in the group who were receiving insulin
prior to ICU admission may also have had type 2 diabetes.
Although speculative in both cases, the clearest message is
that ICU patients admitted with DKA who were not re-
ceiving insulin prior to admission need particular atten-
tion in view of their greater risk. It is noteworthy in this
Table 5 Multivariable logistic regression model for factors
associated with in-hospital mortality: highest sodium in first 24
hours)
Adjusted odds ratio (95 % CI) P value
ANZROD 1.12 (1.10–1.14) <0.001
Highest sodium in




135–144 1.00 Reference category
145–154 2.57 (1.56–4.23)
≥155 2.17 (1.01–4.66)
ANZROD Australian and New Zealand risk of death model with sodium
component removed, CI Confidence interval
Table 6 Multivariable logistic regression model for factors
associated with in-hospital mortality: highest potassium in first
24 hours)
Adjusted odds ratio (95 % CI) P value
ANZROD 1.13 (1.11–1.15) <0.001
Highest potassium in




3.5–4.9 1.00 Reference category
5.0–5.9 1.99 (1.27–3.10)
≥6.0 1.59 (0.83–3.04)
ANZROD Australian and New Zealand risk of death model with potassium
component removed, CI Confidence interval
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context that newer drugs for diabetes management such
as the sodium–glucose co-transporter-2 (SGLT2) inhibi-
tors, which promote glucose loss by the kidney, may pre-
dispose patients with type 2 diabetes to DKA [35]. Our
findings from Australia and New Zealand ICUs should be
generalisable to other developed healthcare systems in-
cluding Europe and the USA. Finally, the observation that
elevated urea concentrations have prognostic implications
suggests a possible application in patient triage.
Strengths and weaknesses of the study
A unique strength of the present study is the size of the
analysed datasets, originating from a large bi-national
registry of DKA spanning nearly a decade and a half. To
our knowledge, this is the first report of its kind to
present not only epidemiological data but changes over
more than a decade in metabolic indices, management
and outcomes. Furthermore, the database is highly rep-
resentative, by 2012 encompassing over 90 % of all ICU
admissions in Australia and New Zealand. With all data
collected prospectively for routine quality surveillance
purposes, the size of the cohort ensures a robust annual
analysis of biochemical status and mortality rates as re-
cently shown in the assessment of sepsis outcomes [36].
Our study has some limitations. The ANZICS APD
does not record serum or urine ketone concentrations
and does not specify diagnostic criteria for DKA, relying
on treating clinicians to apply accepted standard defini-
tions. In clinical practice, however, the diagnosis of DKA
is often made in the context of the appropriate clinical
setting and the presence of a raised serum or urine ke-
tone concentration, such that the diagnosis is rarely a
difficult diagnostic challenge. Although data are mostly
recorded by trained collectors, the specific accuracy of
diagnostic coding for DKA has not been independently
verified. The APD only records the primary diagnosis
and chronic health conditions, thus acute co-morbidities
are not known. This is important as many DKAs might
not be coded because DKA might not be considered the
primary diagnosis. For example a post-operative patient
with type 2 diabetes and severe abdominal sepsis (due to
a perforation) may present with both conditions, but
ICU staff would only code the surgical condition. Given
the unknown confounding influence of acute co-morbid
conditions, there could be an underestimation of the
true incidence of DKA. However, the ANZICS APD is
recognized as a high-quality clinical registry [21] with
extensive data validation rules and on-site audits of data
quality.
The database in its current format does not capture in-
formation on therapy other than the provision of mechan-
ical ventilation. Although the presence of established
insulin therapy is collected at the time of admission,
categorization of patients as type 1 or type 2 diabetes
mellitus is not available. Also data on fluid, insulin and
other therapies were unavailable. Moreover, serum lac-
tate concentrations were not available for analysis as
they are not captured as part of the APACHE II score.
Therefore, it is difficult to decipher precisely the bur-
den of metabolic acidosis from ketones and non-ketone
anions. Finally, there was no information on the meta-
bolic status and outcomes of patients admitted directly
to the medical wards with DKA. Despite our data dem-
onstrating a rising incidence of ICU DKA admissions,
the overall incidence of DKA admissions to hospital is
unknown given this absence of data.
Conclusions
The incidence of admission to Australia and New Zealand
ICUs with DKA has increased fivefold over more than a
decade, with over a quarter of patients not on established
chronic insulin therapy at presentation and carrying a
significantly worse outcome. A sizeable proportion of pa-
tients not on prior insulin could represent DKA associated
with type 2 diabetes. Several markers of physiological sta-
tus in the first 24 hours of ICU admission have improved
progressively, with overall mortality rates remaining stable
and low. The presence of a raised plasma urea concentra-
tion was strongly predictive of mortality. These findings
provide insights into the potential importance of prior in-
sulin history and presenting plasma urea concentrations
for risk stratification.
Key messages
 The present study examined changes in the
epidemiology, national burden, management and
Table 7 Multivariable logistic regression model for factors
associated with in-hospital mortality: urea and creatinine)
Adjusted odds ratio (95 % CI) P value
ANZROD 1.10 (1.08–1.12) <0.0001
Urea (mmol) <0.001











ANZROD Australian and New Zealand risk of death model with urea and
creatinine components removed, CI Confidence interval
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outcomes of severe diabetic ketoacidosis (DKA)
requiring ICU admission across 171 ICUs in Australia
and New Zealand, spanning over a decade and a half
(2000–2013).
 Our data demonstrate significant changes in the
epidemiology, management and some outcomes of
DKA in Australia and New Zealand, with several
factors potentially driving such changes.
 The demonstration that patients who are not on
established insulin therapy represent a quarter of
such patients and are at greater risk of unfavourable
outcomes implies that such patients do develop DKA
and require specific attention. This notion has
important epidemiologic, diagnostic and management
implications
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